| | | | Lifecycle Pharmaceutical | | Interest Rate = 5% |
| | Assumptions for Valuation |
| | Drug Candidate | Current Stage | Complete Phase I | Complete Phase II | Complete Phase III | Drug Approval | Remaining Development Costs |
| | LC-1 | Phase II | NA | Q2 2004 | Q1 2006 | Q2 2007 | $100 MM |
| | LC-2 | Phase II | NA | Q2 2006 | Q2 2008 | Q1 2009 | $300 MM |
| | LC-3 | Phase II | Q1 2004 | Q4 2007 | Q2 2008 | Q2 2008 | $600 MM |
| | LC-4 | Preclinical | Q2 2005 | Q4 2007 | Q1 2009 | Q2 2009 | $220 MM |
| | | PTC-Ph 1 | PTC-Ph 2 | PTC Ph-3 | Probability of Approval | | PTC = Probability of Technical Success |
| | LC-1 | 100% | 40% | 65% | 75% |
| | LC-2 | 100% | 60% | 50% | 50% |
| | LC-3 | 80% | 60% | 60% | 75% |
| | LC-4 | 70% | 50% | 75% | 80% | | Clinical Phase Durations (estimates) |
| | | | | | | | Phase I | 1 year |
| | | Peak Sales | Profit Margins | Annual Expenses | | | Phase II | 730 days |
| | LC-1 | $600 MM | 90% | $40 MM | | | Phase III | 3 years |
| | LC-2 | $800 MM | 90% | $65 MM | | | Drug Regulatory Submission | 0.5 year |
| | LC-3 | $1,000 MM | 80% | $80 MM |
| | LC-4 | $750 MM | 82% | $65 MM |
cjcfor
data_setforPharmaceutical.xlsx
